Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-06-04
1996-06-11
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514254, 514255, 514256, 544238, 544333, 544361, 546 86, 546 87, C07D40104, C07D47104, A61K 3144, A61K 31495
Patent
active
055256112
ABSTRACT:
The invention provides lavendamycin analogs having the following formula: ##STR1## wherein X, Y and R.sup.1 through R.sup.9 are defined in the specification, and salts of these analogs. The invention also provides a method of making the lavendamycin analogs. The lavendamycin analogs have antitumor and antimicrobial activity.
REFERENCES:
patent: 3372090 (1968-03-01), Marsh et al.
patent: 3804947 (1974-04-01), Rao
patent: 5158960 (1992-10-01), Meyers et al.
Behforouz et al., Journal of Organic Chemistry, vol. 58, No. 25, pp.-7089-7091 (Dec. 3, 1993).
Gutsche et al., Journal of Organic Chemistry, vol. 50, No. 26, pp.-Dec. 27, 1985.
Behforouz et al., Abstract of a presentation at the Indiana Academy Of Science, Nov. 5-6, 1992.
Behforouz et al., Abstract of a presentation at the 33rd National Organic Chemistry Symposium, Jun. 13-17, 1993.
Behforouz et al., J. Org. Chem., 58, 7089 (1993).
Boger et al., J. Org. Chem., 50, 5790 (1985).
Boger et al., J. Med. Chem., 30, 1918 (1987).
Kende et al., Tetrahedron Letters, 25, 923 (1984).
Preobrazhenskaya et al., J. Antibiot., 45, 227 (1992).
Rao, Cancer Chemother. Rep. (Part 2), 4, 11 (1974).
Rao, Recent Progress in Chemical Synthesis of Antibiotics, 497-531 (Lukacs et al., ed., 1990).
Rao et al., J. Heterocyclic Chem., 12, 731 (1975).
Rao et al., J. Heterocyclic Chem., 16, 1241 (1979).
Rao et al., Indian J. Chem., 23B, 496 (1984).
Rao et al., Tetrahedron, 42, 5065 (1986).
Rao et al., J. Med. Chem., 34, 1871 (1991).
Renault et al., Eur. J. med. Chem., 16, 24-34 (1981).
Renault et al., Eur. J. med. Chem., 16 545-50 (1981).
Baron et al., Eur. J. med. Chem., 18, 134-38 (1983).
Rivers et al., Cancer Chemotherapy Rep., 46, 17 (1965).
Shaikh et al., Diss. Abs. Inter., 44, 1464B (1983).
Kremer et al., Biochem. Pharmacol., 15, 1111 (1986).
Liao et al., J. Heterocyclic Chem., 13, 1063 (1976).
Liao et al., J. Heterocyclic Chem., 13, 1283 (1976).
Liu et al., J. Antibiot., 45, 454-57 (1992).
Lown et al., Can. J. Chem., 54, 2563 (1976).
Lown et al., Can. J. Biochem., 54, 446 (1976).
Miyasaka et al., J. Chem. Soc. Perkin Trans., 1, 479 (1986).
Mizuno, Biochem. Pharmacol., 16, 933 (1967).
Okada et al., J. Antibiot., 40, 230 (1987).
Okada et al., J. Antibiot., 39, 306 (1986).
Panek et al., Diss. Abs. Inter., 46, 1176B (1985).
Renault et al., J. Med. Chem., 26, 1715-1719 (1983).
Balitz et al., J. Antibiot., 35, 259 (1982).
Basha et al., J. Am. Chem. Soc., 102, 3962 (1980).
Beach, Diss. Abs. Inter., 49, 3204-B (1989).
Behforouz, PRF Annual Report, p. 20 (1990).
Behforouz, PRF Annual Report, p. 119 (1989).
Behforouz, PRF Annual Report, p. 311 (1988).
Boger et al., Tetrahedron Lett., 25, 3175 (1984).
Boger et al., J. Org. Chem., 50, 5782 (1985).
Boger et al., J. Org. Chem., 50, 5790 (1985).
Boger et al., Heterocycles, 24, 1067 (1986).
Boger et al., J. Med. Chem., 30, 1918 (1987).
Chaube et al., Cancer Chemother. Rep. (Part 1), 53, 23 (1969).
Chirigos et al., Cancer Chemother. Rep. Part 1, 57, 305 (1973).
Doyle et al., Tetrahedron Letters, 22, 4595 (1981).
Driscoll et al., Cancer Chemother. Rep. (Part 2), 4, 1 (1974).
Erikson, Diss. Abs. Inter. 49, 747-B (1988).
Gould et al., Fortschr. Chem. Org. Naturst., 41, 77, (1982).
Harris et al., Cancer, 18, 49 (1965).
Herlt et al., J. Antibiot. 38, 516 (1985).
Hibino et al., J. Org. Chem., 42, 232 (1977).
Hibino et al. Heterocycles, 20, 1957 (1983).
Hibino et al., Heterocycles, 23, 261 (1985).
Hibino et al., Chem. Pharm. Bull., 34, 1376 (1986).
Inouye et al., J. Antibiot., 38, 1429 (1985).
Inouye et al., J. Antibiot., 39, 550 (1986).
Inouye et al., J. Antibiot., 40, 105 (1987).
Kaung et al., Cancer, 23, 1280 (1969).
Kende et al., Heterocycles, 21, 91 (1984).
Kende et al., J. Am. Chem. Soc., 103, 1271 (1981).
Kende et al., Tetrahedron Lett., 48, 4775 (1978).
Kitahara et al., Chem Pharm. Bull., 38, 2841 (1990).
Kremer et al., Cancer Chemother. Rep., 51, 19 (1967).
Liao et al., Angew. Chem. Intern. Edit., 6, 82 (1967).
Molina et al., Tetrahedron Lett., 33, 2891 (1992).
Rao, J. Heterocyclic Chem., 12, 725 (1975).
Rao, J. Heterocyclic Chem., 14, 653 (1977).
Rao et al., J. Am. Chem. Soc., 85, 2532 (1963).
Shaikh et al., J. Med. Chem., 29, 1329 (1986).
Shibata et al., J. Antibiot., 33, 1231 (1980).
Take et al., J. Antibiot., 40, 679 (1987).
Take et al., J. Antibiot., 42, 968 (1989).
Tolstikov et al., J. Antibiot., 45, 1002 (1992).
Tolstikov et al., J. Antibiot., 45, 1020 (1992).
Weinreb et al., J. Am Chem. Soc., 104, 536-44 (1982).
Wittek et al., J. Org. Chem., 44, 870 (1979).
Yasuda et al., J. Antibiot., 24, 1253 (1987).
Behforouz Mohammad
Merriman Ronald L.
LandOfFree
Lavendamycin analogs and methods of making and using them does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lavendamycin analogs and methods of making and using them, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lavendamycin analogs and methods of making and using them will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-351817